Neurology
Clene's CNM-Au8 Shows Promise in Parkinson's Disease Preclinical Study
Clene Inc. presented preclinical data demonstrating its investigational drug CNM-Au8 improves mitochondrial function and reduces inflammation in Parkinson's disease models, potentially offering a new neuroprotective treatment approach.
New Research Identifies SOX6 Protein as Potential Key to Myelin Repair in Multiple Sclerosis
Groundbreaking research published in Cell reveals that targeting the SOX6 protein could enable myelin repair in multiple sclerosis patients, potentially opening new therapeutic avenues for the neurodegenerative disease.
InFlectis BioScience and Aix Marseille Université Expand IFB-088's Therapeutic Potential to Axonal Charcot-Marie-Tooth Disease
InFlectis BioScience and Aix Marseille Université have demonstrated that lead compound IFB-088 shows efficacy in animal models of axonal Charcot-Marie-Tooth disease type 2A, expanding its potential to address multiple CMT subtypes with no approved treatments.
Study Links Head Injuries to Increased Brain Cancer Risk, Driving Treatment Research
A Mass General Brigham study of 75,000 patients reveals traumatic brain injuries elevate malignant brain tumor risk, highlighting the importance of ongoing treatment development by companies like CNS Pharmaceuticals Inc.
Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference
Annovis Bio's CEO will present at the H.C. Wainwright conference, highlighting the company's focus on developing innovative therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.
Blocking Brain Damage from Glioblastoma May Slow Tumor Growth and Extend Cognitive Function
New research from University College London suggests that preventing brain damage caused by glioblastoma could significantly slow tumor progression and preserve cognitive function longer in patients.
Clene Inc. Advances Toward NDA Submission for ALS Treatment CNM-Au8, Extends Financial Runway
Clene Inc. is preparing to submit a New Drug Application for its ALS treatment candidate CNM-Au8 by year-end 2025 while securing financial stability through recent financing that extends its cash runway into early 2026.
Lantern Pharma Launches AI Tool predictBBB.ai to Revolutionize CNS Drug Development with 94% Accuracy
Lantern Pharma's new AI platform predictBBB.ai addresses the critical challenge of blood-brain barrier permeability in drug development, potentially accelerating treatments for neurological diseases with unprecedented 94% prediction accuracy.
Study Reveals B-Vitamin Supplements Could Offer New Hope for Parkinson’s Disease Patients
A recent study highlights the potential of B-vitamin supplements in addressing some medical needs of Parkinson’s disease patients, suggesting a simple yet effective treatment option.
Clene Inc. Advances Toward FDA Submission for ALS Therapy with Promising Q2 2025 Results
Clene Inc. reports significant progress in its Q2 2025 results, targeting a year-end NDA submission for its ALS therapy, CNM-Au8, with sufficient cash runway into Q1 2026.
Understanding the Risks and Treatments of Benign Brain Tumors in Women
This article highlights the increased risk of benign brain tumors in women and the importance of recognizing early symptoms, while also discussing current treatment options and ongoing research efforts.
Oragenics Inc. Advances Toward Phase IIa Concussion Trial with ONP-002
Oragenics Inc. (NYSE American: OGEN) is making significant progress with its lead candidate, ONP-002, aiming to become the first FDA-approved pharmacological treatment for concussion, highlighting the potential of its intranasal delivery technology in transforming neurological care.
Quantum BioPharma's PET Tracer Shows Promise in Monitoring Myelin Integrity in Multiple Sclerosis
Quantum BioPharma Ltd.'s collaboration with Massachusetts General Hospital has yielded a PET tracer capable of detecting MS lesions invisible to conventional MRI, marking a significant advancement in the monitoring and treatment of multiple sclerosis.
Annovis Bio Inc. Secures Comprehensive Patent Coverage for Buntanetap, Enhancing Treatment Prospects for Neurodegenerative Diseases
Annovis Bio Inc. has expanded its patent portfolio to cover a new crystalline form of buntanetap, promising improved stability and bioequivalence for treating neurodegenerative diseases like Alzheimer's and Parkinson's, with protection extending through 2046.
Clene Inc. to Showcase Neurodegenerative Disease Treatments at Canaccord 45th Annual Growth Conference
Clene Inc. will present its innovative treatments for neurodegenerative diseases at the Canaccord 45th Annual Growth Conference, highlighting potential advancements in ALS and MS therapy.
Lantern Pharma Introduces AI Tool PredictBBB.ai(TM) with 94% Accuracy in Predicting Blood-Brain Barrier Permeability
Lantern Pharma's new AI module, predictBBB.ai(TM), significantly enhances the prediction of small molecules' ability to cross the blood-brain barrier, addressing a major challenge in drug development.
Exploring the Link Between TMJ/TMD and Severe Headaches Through Neuromuscular Dentistry
A new article highlights the connection between TMJ/TMD disorders and severe headaches, offering insights into treatment options like Sphenopalatine Ganglion Blocks and Neuromuscular Dentistry.
AI-Based Speech Tool Offers Early Detection Potential for Parkinson’s Disease
A new AI-based speech screening tool developed by computer scientists could revolutionize the early detection of Parkinson’s disease, offering patients a better chance at effective management of the condition.
Oragenics Inc. Advances ONP-002 Phase IIa Trial with Southern Star Research for Concussion Treatment
Oragenics Inc. partners with Southern Star Research to conduct a Phase IIa trial for ONP-002, an intranasal therapy aimed at treating mild traumatic brain injuries, highlighting a significant step towards addressing the unmet needs in concussion care.
Clene Inc. Advances Toward FDA Approval for ALS Treatment, Highlighting Market Potential
Clene Inc. is making significant progress toward FDA accelerated approval for its ALS drug CNM-Au8®, targeting a $1.3 billion market by 2034 with a novel approach to neurodegenerative diseases.
Clene Inc. Advances Neurodegenerative Disease Treatment with FDA-Backed Biomarker Analysis
Clene Inc. is set to initiate neurofilament biomarker analyses for its drug CNM-Au8 in ALS patients, marking a significant step towards innovative treatments for neurodegenerative diseases.
ReAlta’s Pegtarazimod Demonstrates Potential in Reducing Brain Inflammation in Newborns with HIE
A preclinical study reveals pegtarazimod's ability to significantly reduce brain inflammation in newborns with hypoxic ischemic encephalopathy (HIE), offering hope for a new treatment approach.
Study Reveals Early Health Visits May Predict Multiple Sclerosis Decades Before Diagnosis
A recent study indicates that individuals later diagnosed with multiple sclerosis visit healthcare providers more frequently decades before their diagnosis, suggesting potential for earlier intervention.
Lorati's Nano-Emulsion Offers New Hope for Stroke Recovery
Lorati Co., Ltd. introduces a natural, mineral-based nano-emulsion therapy that promises a non-invasive solution for full recovery from both hemorrhagic and ischemic strokes, marking a significant advancement in stroke treatment.
Jupiter Neurosciences Advances in Treating Neuroinflammation and Aging with JOTROL™ and Nugevia™
Jupiter Neurosciences Inc. is making strides in treating central nervous system disorders and tapping into the longevity market with its innovative products JOTROL™ and Nugevia™, highlighting the potential to combat aging and neuroinflammation.
University of Sydney Researchers Discover Potential Breakthrough in Parkinson's Treatment
A preclinical study by University of Sydney researchers has successfully reversed Parkinson's-like symptoms in mice by targeting a malfunctioning protein, offering hope for future human treatments.
Oragenics Inc. Raises $16.5 Million to Advance Intranasal Concussion Therapy
Oragenics Inc. has successfully closed a $16.5 million public offering to fund the development of its intranasal therapy for concussions, marking a significant step forward in neurological disorder treatments.
InFlectis BioScience's IFB-088 Shows Promise in ALS Treatment Through Groundbreaking Study
InFlectis BioScience's study on IFB-088 demonstrates potential in addressing TDP-43 proteinopathy, offering hope for ALS patients by improving motor neuron survival and function.
Oragenics Inc. Announces $20 Million Preferred Stock and Warrant Offering to Fund Concussion Trials and R&D
Oragenics Inc. secures up to $20 million through a preferred stock and warrant offering to advance its ONP-2 concussion trials and support R&D efforts.
Clene Inc. Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs
Clene Inc. progresses in its regulatory strategy for CNM-Au8, with FDA meetings set to discuss ALS and MS treatments, marking a significant step towards potential accelerated approval.